Literature DB >> 1648448

A receptor tyrosine kinase specific to hematopoietic stem and progenitor cell-enriched populations.

W Matthews1, C T Jordan, G W Wiegand, D Pardoll, I R Lemischka.   

Abstract

To elucidate the molecular biology of the hematopoietic stem cell, we have begun to isolate genes from murine cell populations enriched in stem cell activity. One such cDNA encodes a novel receptor tyrosine kinase, designated fetal liver kinase-2 or flk-2, which is related to the W locus gene product c-kit. Expression analyses suggest an extremely restricted distribution of flk-2. It is expressed in populations enriched for stem cells and primitive uncommitted progenitors, and is absent in populations containing more mature cells. Therefore, this receptor may be a key signal transducing component in the totipotent hematopoietic stem cell and its immediate self-renewing progeny.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1648448     DOI: 10.1016/0092-8674(91)90010-v

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  94 in total

1.  Characterization and distribution of a new cell surface marker of neuronal precursors.

Authors:  W Schubert; V Coskun; M Tahmina; M S Rao; M B Luskin; Z Kaprielian
Journal:  Dev Neurosci       Date:  2000       Impact factor: 2.984

2.  The influence of extra-cellular matrix and stroma remodeling on the productivity of long-term human bone marrow cultures.

Authors:  R M Schwartz; J Caldwell; M F Clarke; S G Emerson; B O Palsson
Journal:  Cytotechnology       Date:  1992       Impact factor: 2.058

3.  Selective KIT inhibitor KI-328 and HSP90 inhibitor show different potency against the type of KIT mutations recurrently identified in acute myeloid leukemia.

Authors:  Akane Tsujimura; Hitoshi Kiyoi; Yukimasa Shiotsu; Yuichi Ishikawa; Yumiko Mori; Hiroshi Ishida; Tsutomu Toki; Etsuro Ito; Tomoki Naoe
Journal:  Int J Hematol       Date:  2010-10-05       Impact factor: 2.490

Review 4.  Biology, clinical relevance, and molecularly targeted therapy in acute leukemia with FLT3 mutation.

Authors:  Hitoshi Kiyoi; Tomoki Naoe
Journal:  Int J Hematol       Date:  2006-05       Impact factor: 2.490

Review 5.  Clinical significance of FLT3 in leukemia.

Authors:  Hitoshi Kiyoi; Masamitsu Yanada; Kazutaka Ozekia
Journal:  Int J Hematol       Date:  2005-08       Impact factor: 2.490

6.  Hoxa9 regulates Flt3 in lymphohematopoietic progenitors.

Authors:  Kimberly Gwin; Elena Frank; Ayoko Bossou; Kay L Medina
Journal:  J Immunol       Date:  2010-10-22       Impact factor: 5.422

Review 7.  Hematopoietic cytokines.

Authors:  Donald Metcalf
Journal:  Blood       Date:  2008-01-15       Impact factor: 22.113

8.  FGF2 posttranscriptionally down-regulates expression of SDF1 in bone marrow stromal cells through FGFR1 IIIc.

Authors:  Takayuki Nakayama; Noriko Mutsuga; Giovanna Tosato
Journal:  Blood       Date:  2006-10-31       Impact factor: 22.113

9.  Long-term repopulation of hematolymphoid cells with only a few hemopoietic stem cells in mice.

Authors:  H Ogata; W G Bradley; M Inaba; N Ogata; S Ikehara; R A Good
Journal:  Proc Natl Acad Sci U S A       Date:  1995-06-20       Impact factor: 11.205

10.  In vivo evidence for an instructive role of fms-like tyrosine kinase-3 (FLT3) ligand in hematopoietic development.

Authors:  Panagiotis Tsapogas; Lee Kim Swee; Anja Nusser; Natko Nuber; Matthias Kreuzaler; Giuseppina Capoferri; Hannie Rolink; Rhodri Ceredig; Antonius Rolink
Journal:  Haematologica       Date:  2014-01-24       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.